Organogenesis Holdings Inc. (ORGO)

From the record

Organogenesis Holdings Inc.'s filings since 2017 show 10 warning events of 3 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2024-11-13); a notice about its exchange listing (8-K item 3.01, 8 times, the latest 2021-05-27); an auditor change (8-K item 4.01, the latest 2018-12-11) (its current reports).

From the record

Organogenesis Holdings Inc.'s 10 filed years say what it did: revenue went from $139 million in fiscal 2016 to $564 million in fiscal 2025, up 16.9% a year; it rose in 6 of 9 years; the deepest fall was 7% from fiscal 2021 to fiscal 2023; net income was positive in 6 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Organogenesis Holdings Inc.'s diluted share count shrank about 0.5% a year, and dividends and buybacks returned about 73% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 4 sales and 2 purchases of their own stock on the open market in the year to 2026-09-30, buying about $40 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Organogenesis Holdings Inc. earned about 12 cents of profit for every dollar of shareholders' money. Leverage: it owed about 50 cents per dollar of assets, and net share issuance: its share count shrank 1.1% over the year (the filed statements).

From the record

Organogenesis Holdings Inc.'s standing among 315 graded names in its industry family: revenue of $564 million in fiscal 2025 ranks in the top 18% by size; a net margin of 6.6% ranks in the top 20%; revenue growth of 7.8% a year over the last 3 filed years ranks in the bottom 49% (its annual reports).

From the record

Organogenesis Holdings Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Gillheeney, Gary S. (President and CEO, as filed), filing under that title since 2018-12-12, 7.9 years (top 24% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 5.6 years (top 50%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Organogenesis Holdings Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $94 million against no long-term debt tagged leaves 15.8% of its assets as net cash, bottom 34% of its family; cash from operations less capital spending is -4.3% of revenue (top 31%); research spending of 7.9% of revenue (bottom 12%) (its annual report).

From the record

Organogenesis Holdings Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 7.8% a year over the last three filed years against 16.9% over all 10, slowing (bottom 36% of its family); the newest year grew 17% (top 40%); research spending grew 3.9% a year (top 48%); capital spending grew -25.3% a year (bottom 40%) (its annual reports). Organogenesis Holdings Inc. reported 2 product lines in fiscal 2025: Product at $563 million (100%), Grant at $1 million (0%); 1 of 1 grew against the year before (its annual report).

From the record

Organogenesis Holdings Inc.'s newest year against its own record: revenue of $564 million in fiscal 2025 came in 13.2% above the $498 million its prior three years' pace pointed to (top 31% of its family); net income of $37 million against a prior three-year average of $7 million (top 4%); a net margin of 6.6% against 1.6% before (bottom 43%) (its annual reports).